Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
Tumor associated neutrophils have been correlated with poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Here the authors show that the tyrosine kinase inhibitor lorlatinib modulates neutrophil development and recruitment in the tumor microenvironment, attenuating PDAC progres...
Guardado en:
Autores principales: | Sebastian R. Nielsen, Jan E. Strøbech, Edward R. Horton, Rene Jackstadt, Anu Laitala, Marina C. Bravo, Giorgia Maltese, Adina R. D. Jensen, Raphael Reuten, Maria Rafaeva, Saadia A. Karim, Chang-Il Hwang, Luis Arnes, David A. Tuveson, Owen J. Sansom, Jennifer P. Morton, Janine T. Erler |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/80c3347050694832b4503df3a10d5b8d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Hayato Mizuta, et al.
Publicado: (2021) -
CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
por: A. V. Bogolyubova, et al.
Publicado: (2015) -
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Haoxin Li, et al.
Publicado: (2019) -
Predictors of responses to immune checkpoint blockade in advanced melanoma
por: N. Jacquelot, et al.
Publicado: (2017) -
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Xiaopin Duan, et al.
Publicado: (2019)